Dr. Schuehsler serves as Chairman and CEO of TVM Capital Healthcare in Dubai and Singapore. TVM Capital Healthcare is a private equity investment platform created in 2009 focused on investing in and building transformational healthcare companies in the fast-growing emerging economies of the Middle East and Southeast Asia, including the expansion of Western companies into these regions.
Most recently TVM Capital Healthcare announced the first closing of its new Southeast Asia Fund, following the oversubscribed closing of its growth capital fund with a focus on Saudi Arabian healthcare transformation at USD 254M in late 2024. With this fund, the firm intends to mobilize total capital for investment in Saudi growth companies of more than USD 500M for about 10 portfolio companies in sub-sectors such as medical product manufacturing and single specialty clinics in fields such as post-acute and chronic care, home health and disease management, reproductive medicine, oncology, cardiology and the rapidly growing field of digital health solutions.
Dr. Schuehsler served as chairman or director of several healthcare growth companies since 2010, both in the field of specialized clinics as well as medical device manufacturing and longevity medicine. He also holds a director position of cancer therapy company, invIOs Holding AG, in Vienna, Austria.
Dr. Schuehsler joined the original TVM Capital company (Techno Venture Management GmbH) in 1990 in Munich. From the beginning, he led the firm’s life science practice and later as Managing Partner he steered the firm through several transitions of ownership and strategy. He raised close to USD 1.2bn, was the deal maker on more than 30 direct investments in life science companies in Europe and the U.S., oversaw more than 100 investments in the health industry by teams out of Munich and Boston and had more than 50 IPOs and 30 M&A exit transactions in the portfolio. His tenure with TVM Capital ended in 2012. During his tenure as Managing Partner, he developed TVM Capital into the leading and largest life science investor in Germany in the 1990s, one of the leading European firms in the sector and one of the most active U.S. East Coast life science investors in the 2000’s.
Starting in 2007, he spearheaded the expansion of TVM Capital into the field of emerging market healthcare private equity which was eventually domiciled in Dubai in 2009 and expanded to Singapore in late 2020. In 2010, he and co-founder, Hoda Abou-Jamra, bought out the German company and partners and established TVM Capital Healthcare as a fully independent entity.
In terms of industry representation, from 2003 to 2007, Dr. Schuehsler served as chairman of the Professional Standards Committee of the European Private Equity and Venture Capital Association (EVCA, now “Invest Europe”), where he led a team of up to 10 finance, audit and legal specialists as well as industry practitioners in the development and improvement of PE/VC industry guidance documents, such as the EVCA Code of Conduct. In 2007, he was elected chairman of EVCA for the usual one-year term Dr. Schuehsler also was as a member of the Technology Advisory Committee to chancellor Helmut Kohl in Germany. In 2014-2017, he served on the Steering Committee of the MENA Private Equity Association.
Dr. Schuehsler also was a member of the Technology Advisory Committee to chancellor Helmut Kohl in Germany, was a board member of Max-Planck Innovation GmbH in Munich for more than 10 years and for several years was a member of the Selection Committee for the Technology Pioneers program of the World Economic Forum (WEF).